# Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）

> **NCT02388919** · PHASE2,PHASE3 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 439 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02388919
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-26
- **Primary completion:** 2017-01-05
- **Final completion:** 2017-01-06
- **Target enrollment:** 439 (ACTUAL)
- **Last updated:** 2017-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02388919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02388919, "Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02388919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*